The global dysmenorrhea treatment market was valued at US$ 5,937.8 million by the end of the year 2022. In the current year 2023, the global demand for dysmenorrhea treatment services is estimated to be valued at US$ 6,324.5 million. A year-on-year growth rate of 8.3% is expected for the market during the forecast period from 2023 to 2033. By following this significant CAGR, the global market value is projected to reach US$ 13,906.5 million by 2033.
Dysmenorrhea is a clinical term for menstrual cramps in which a woman experiences severe pain or cramps in her abdominal area that may spread to her lower legs and back. Most women begin suffering from dysmenorrhea throughout adolescence, generally after four to five years of the first menstrual cycle.
Prostaglandins are substances that are produced in the uterine lining during menstruation. These prostaglandins generate uterine muscular spasms, which cause discomfort and reduce blood supply and oxygen to the uterus. Menstrual problems can be caused by a wide range of underlying conditions.
Lifestyle modifications, changes in the environment, and food preferences all have a significant influence on human bodies, which has also raised the occurrence of dysmenorrhea among women. Also, the increased frequency of dysmenorrhea has led to increased health consciousness among women to treat the illness, which is projected to drive market growth.
The increased consumer awareness of dysmenorrhea therapy, as well as the low cost of over-the-counter medications, are two important factors driving growth in the market. Moreover, the increased usage of drugs to relieve pain during menstruation, in turn, drives the growth of the worldwide dysmenorrhea treatment market.
The increase in technological improvement in the healthcare industry is likely to fuel the growth of the market throughout the forecast period. However, long-term treatment’s side effects and issues, the high morbidity of menstrual cramps leading to inadequate treatments, and traditional family values are expected to stymie the growth of the dysmenorrhea treatment industry.
| Report Attributes or Data Points | Details |
|---|---|
| Global Dysmenorrhea Treatment Market Valuation in 2022 | US$ 5,937.8 million |
| Estimated Global Market Share in 2023 | US$ 6,324.5 million |
| Forecasted Global Market Size by 2033 | US$ 13,906.5 million |
| Projected Global Market Growth Rate from 2023 to 2033 | 8.3% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 5.4% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The growing healthcare spending, which aids in the improvement of infrastructure, is a crucial element driving the development rate of the market. Furthermore, numerous government organizations intend to improve healthcare infrastructure by boosting financing, which might have an impact on market dynamics.
People's changing lifestyles are expected to have an impact on market dynamics throughout the projected period from 2023 to 2033. Changing lifestyles, along with bad eating habits, have a significant influence on the human body. As a result, the prevalence of dysmenorrhea/menstrual cramps among women has increased. Climate factors are also thought to increase the likelihood of menstruation cramps.
A growing number of government measures to raise awareness and increase the aging population might result in market expansion. Additionally, increased disposable income and urbanization are estimated to boost the market's growth rate.
The high cost of care, on the other hand, is likely to impede the growth rate of the overall market during the forecast period between 2023 and 2033. The global market could face challenges due to a lack of healthcare infrastructure in emerging nations and a stringent regulatory environment. Furthermore, a lack of public awareness and inadequate reimbursement policies may hinder market expansion during the projection period from 2023 to 2033.
Challenges related to long-term care and other side effects and issues, the high morbidity of menstrual cramps due to insufficient treatments, and traditional family values are expected to stymie the growth of the global market.
Principal Consultant
The endometriosis segment is expected to gain a global market share of 35% during the forecast period. Furthermore, the rising prevalence of endometriosis is projected to drive the global market forward.
The global prevalence of disorders such as endometriosis, the primary cause of secondary dysmenorrhea, is also increasing. Endometriosis affects an estimated 1 in 10 women throughout their reproductive years, or around 176 million people globally, according to an article titled Understanding Endometriosis - the Basics published in July 2021. This factor is predicted to have a substantial influence on market growth. As a result of the aforementioned causes, the non-steroidal anti-inflammatory medicines category is predicted to considerably contribute to market growth.
| Category | By Disease Type |
|---|---|
| Top Segment | Primary Dysmenorrhea |
| Market Share in Percentage | 63.4% |
| Category | By Therapeutic Class |
|---|---|
| Top Segment | Non-steroidal Anti-inflammatory drugs (NSAIDs) |
| Market Share in Percentage | 35.4% |
In terms of market share and revenue, North America’s market is expected to be the dominant market for dysmenorrhea treatments during the projection period from 2023 to 2033. The analysts at Future Market Insights observed that in 2022, the market of dysmenorrhea treatment in North America acquired a global market share of 37.2%. This will maintain its supremacy throughout the projected period.
Technological innovation and increased healthcare spending is going to propel the market's growth rate in this area even fast. Furthermore, the presence of significant key competitors and rising pharmaceutical consumption are a few other factors that are estimated to fuel the market's development rate in this area notably
Furthermore, growth in research and development procedures for generating new pharmaceuticals and assessing the potential of existing therapies may improve the market under consideration. For example,
A January 2019 research titled Continuous vs. cyclic combined hormonal contraceptives for the treatment of dysmenorrhea: a comprehensive review found that flexible/extended combined hormonal contraceptives (CHC) culminated in four few days of dysmenorrhea than the cyclic regimen. Such research projects are likely to considerably contribute to the market's growth.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 37.2% |
| Europe | 24.2% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By 2022, Europe held around 24.2% of the global market share. This region is expected to be one of the significantly growing markets for dysmenorrhea treatment during the forecast period.
The increasing number of research and development activities is driving the market's expansion further. This could give advantageous chances for the expansion of the dysmenorrhea treatment market. Also, leading corporations are investing in research and development. This brings up a lot of market opportunities.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| The United States | 29.5% |
| Germany | 5.1% |
| Japan | 5.1% |
The Asia Pacific region is expected to develop at a significant CAGR during the forecast period. This is owing to a rise in the prevalence of dysmenorrhea and menstrual health issues in this region for treatment. Furthermore, the expansion of healthcare infrastructure and growing government efforts might accelerate the market's growth rate in this area.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| The United Kingdom | 6% |
| China | 11% |
| India | 9% |
| Australia | 5.3% |
The key players of this market include Novartis Pharmaceuticals Corporation, Merck, Inc., Bayer Schering Pharma AG, Vanita Therapeutics, Nua, Cora, Alvogen, Pfizer, Inc., Roche Laboratories, Taj Pharmaceuticals, Ltd., Sanofi, and Terramedic, Inc.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 8.2% from 2023 to 2033 |
| Market value in 2023 | US$ 6,324.5 million |
| Market value in 2033 | US$ 13,906.5 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | US$ million for Value |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization Scope | Available on Request |
The market is valued at US$ 6,324.5 million in 2023.
A CAGR of 11% is predicted for China by 2033.
The market is projected to reach US$ 13,906.5 million in 2033.
The market is occupied by primary dysmenorrhea in disease type with a share of 63.4%.
The market was valued at US$ 5,937.8 million in 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diseases
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Diseases, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diseases, 2023 to 2033
5.3.1. Primary Dysmenorrhea
5.3.2. Secondary Dysmenorrhea
5.3.3. Endometriosis
5.3.4. Adenomyosis
5.3.5. Uterine Myomas
5.3.6. Endometrial Polyps
5.3.7. Cervical Stenosis
5.3.8. Obstructive Malformations Of Genital Tract
5.4. Y-o-Y Growth Trend Analysis By Diseases, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Diseases, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic Class
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Class, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Class, 2023 to 2033
6.3.1. Non-Hormonal Medical Treatment
6.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
6.3.3. Non-Selective Nsaids
6.3.4. Cox-2 Inhibitors
6.3.5. Transdermal Glyceryl Trinitrate
6.3.6. Over-The-Counter (Otc) Medications
6.3.7. Hormonal Medicine Treatment
6.3.8. Combined Oral Contraceptive
6.3.9. Progestin Regimens
6.3.10. Surgical Options
6.3.11. Laparoscopy
6.3.12. Hysterectomy
6.4. Y-o-Y Growth Trend Analysis By Therapeutic Class, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Therapeutic Class, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Diseases
8.2.3. By Therapeutic Class
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Diseases
8.3.3. By Therapeutic Class
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Diseases
9.2.3. By Therapeutic Class
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Diseases
9.3.3. By Therapeutic Class
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Diseases
10.2.3. By Therapeutic Class
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Diseases
10.3.3. By Therapeutic Class
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Diseases
11.2.3. By Therapeutic Class
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Diseases
11.3.3. By Therapeutic Class
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Diseases
12.2.3. By Therapeutic Class
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Diseases
12.3.3. By Therapeutic Class
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Diseases
13.2.3. By Therapeutic Class
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Diseases
13.3.3. By Therapeutic Class
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Diseases
14.2.3. By Therapeutic Class
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Diseases
14.3.3. By Therapeutic Class
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Diseases
15.1.2.2. By Therapeutic Class
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Diseases
15.2.2.2. By Therapeutic Class
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Diseases
15.3.2.2. By Therapeutic Class
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Diseases
15.4.2.2. By Therapeutic Class
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Diseases
15.5.2.2. By Therapeutic Class
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Diseases
15.6.2.2. By Therapeutic Class
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Diseases
15.7.2.2. By Therapeutic Class
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Diseases
15.8.2.2. By Therapeutic Class
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Diseases
15.9.2.2. By Therapeutic Class
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Diseases
15.10.2.2. By Therapeutic Class
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Diseases
15.11.2.2. By Therapeutic Class
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Diseases
15.12.2.2. By Therapeutic Class
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Diseases
15.13.2.2. By Therapeutic Class
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Diseases
15.14.2.2. By Therapeutic Class
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Diseases
15.15.2.2. By Therapeutic Class
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Diseases
15.16.2.2. By Therapeutic Class
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Diseases
15.17.2.2. By Therapeutic Class
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Diseases
15.18.2.2. By Therapeutic Class
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Diseases
15.19.2.2. By Therapeutic Class
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Diseases
15.20.2.2. By Therapeutic Class
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Diseases
15.21.2.2. By Therapeutic Class
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Diseases
15.22.2.2. By Therapeutic Class
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Diseases
15.23.2.2. By Therapeutic Class
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Diseases
16.3.3. By Therapeutic Class
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Novartis Pharmaceuticals Corporation,
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Merck, Inc.,
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Bayer Schering Pharma AG,
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Vanita Therapeutics,
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Alvogen,
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Pfizer, Inc.,
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Nua
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Cora
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Roche Laboratories,
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Taj Pharmaceuticals, Ltd.,
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Dysmenorrhea Treatment Market
